Marker Therapeutics, Inc.
MRKR
$1.19
$0.00320.27%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.25M | 1.93M | 1.17M | 1.24M | 1.06M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.25M | 1.93M | 1.17M | 1.24M | 1.06M |
| Cost of Revenue | 5.09M | 3.47M | 2.34M | 2.58M | 2.62M |
| Gross Profit | -2.83M | -1.55M | -1.17M | -1.33M | -1.56M |
| SG&A Expenses | 1.03M | 854.70K | 1.14M | 1.22M | 1.38M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.11M | 4.33M | 3.48M | 3.79M | 3.99M |
| Operating Income | -3.86M | -2.40M | -2.31M | -2.55M | -2.94M |
| Income Before Tax | -3.79M | -2.31M | -2.19M | -2.39M | -2.74M |
| Income Tax Expenses | 50.00K | -- | -- | -- | 3.70K |
| Earnings from Continuing Operations | -3.84M | -2.31M | -2.19M | -2.39M | -2.74M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -62.90K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.84M | -2.31M | -2.19M | -2.39M | -2.80M |
| EBIT | -3.86M | -2.40M | -2.31M | -2.55M | -2.94M |
| EBITDA | -- | -- | -- | -- | -2.24M |
| EPS Basic | -0.42 | -0.26 | -0.25 | -0.27 | -0.32 |
| Normalized Basic EPS | -0.26 | -0.16 | -0.15 | -0.17 | -0.19 |
| EPS Diluted | -0.42 | -0.26 | -0.25 | -0.27 | -0.32 |
| Normalized Diluted EPS | -0.26 | -0.16 | -0.15 | -0.17 | -0.19 |
| Average Basic Shares Outstanding | 9.18M | 8.92M | 8.92M | 8.90M | 8.89M |
| Average Diluted Shares Outstanding | 9.18M | 8.92M | 8.92M | 8.90M | 8.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |